{"id":"medi4736-tremelimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Immune-mediated hepatitis"},{"rate":null,"effect":"Immune-mediated colitis"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:18:33.069829","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MEDI4736 is a PD-L1 inhibitor that prevents tumor cells from suppressing immune responses by blocking the PD-L1/PD-1 interaction. Tremelimumab is a CTLA-4 antagonist that removes inhibitory signals on T cells, promoting their proliferation and activation. The combination leverages two complementary immune checkpoint pathways to maximize anti-tumor T-cell responses.","oneSentence":"MEDI4736 (durvalumab) blocks PD-L1 to restore anti-tumor immunity, while tremelimumab blocks CTLA-4 to enhance T-cell activation, together providing dual checkpoint inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:30.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic non-small cell lung cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Mesothelioma"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT07489976","phase":"PHASE2","title":"IIT2025-03-YANG-LIFT-HCC","status":"RECRUITING","sponsor":"Ju Dong Yang","startDate":"2026-04-01","conditions":"Hepato Cellular Carcinoma","enrollment":41},{"nctId":"NCT02537418","phase":"PHASE1","title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-16","conditions":"Solid Malignancies","enrollment":153},{"nctId":"NCT05063565","phase":"PHASE2","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2023-11-03","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT02888743","phase":"PHASE2","title":"Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-14","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":110},{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT03298451","phase":"PHASE3","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Hepatocellular Carcinoma","enrollment":1324},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT04499053","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2020-12-09","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":18},{"nctId":"NCT06796114","phase":"NA","title":"Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-06-25","conditions":"Hepatocellular Carcinoma","enrollment":120},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT07391670","phase":"PHASE1","title":"A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-31","conditions":"Solid Tumours","enrollment":40},{"nctId":"NCT03753919","phase":"PHASE2","title":"Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial","status":"TERMINATED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2019-04-02","conditions":"Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer","enrollment":79},{"nctId":"NCT02812420","phase":"EARLY_PHASE1","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-07","conditions":"Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","enrollment":54},{"nctId":"NCT03057106","phase":"PHASE2","title":"Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2017-03-28","conditions":"Lung Cancer Metastatic","enrollment":301},{"nctId":"NCT02453282","phase":"PHASE3","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Non-Small-Cell Lung Carcinoma NSCLC","enrollment":1118},{"nctId":"NCT06608940","phase":"PHASE1, PHASE2","title":"BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT05883644","phase":"PHASE3","title":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-06-27","conditions":"Advanced Hepatocellular Carcinoma","enrollment":111},{"nctId":"NCT04522544","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-12-15","conditions":"Hepatocellular Carcinoma Non-resectable, HCC","enrollment":55},{"nctId":"NCT02519348","phase":"PHASE2","title":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2015-10-19","conditions":"Hepatocellular Carcinoma","enrollment":433},{"nctId":"NCT02542293","phase":"PHASE3","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-03","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":953},{"nctId":"NCT06494540","phase":"","title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-28","conditions":"Non-squamous Metastatic Non-Small-Cell Lung Carcinoma","enrollment":600},{"nctId":"NCT02499328","phase":"PHASE1, PHASE2","title":"Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck","enrollment":340},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT04395079","phase":"PHASE2","title":"Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-07","conditions":"Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":9},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT06824363","phase":"EARLY_PHASE1","title":"ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu","status":"NOT_YET_RECRUITING","sponsor":"University of California, Irvine","startDate":"2026-04","conditions":"Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma","enrollment":34},{"nctId":"NCT07174570","phase":"PHASE2","title":"Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-01-02","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":39},{"nctId":"NCT02516241","phase":"PHASE3","title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-02","conditions":"Urothelial Cancer","enrollment":1126},{"nctId":"NCT03158064","phase":"PHASE2","title":"Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-05-15","conditions":"Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma","enrollment":30},{"nctId":"NCT05154994","phase":"PHASE1","title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2022-01-14","conditions":"Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03539822","phase":"PHASE1, PHASE2","title":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2018-10-22","conditions":"Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma","enrollment":117},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT06855225","phase":"PHASE2","title":"A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Mehmet Akce","startDate":"2026-03","conditions":"Combined Hepatocellular and Cholangiocarcinoma","enrollment":29},{"nctId":"NCT03075527","phase":"PHASE2","title":"A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-04-10","conditions":"Mesothelioma","enrollment":19},{"nctId":"NCT03923270","phase":"PHASE1","title":"Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-06","conditions":"Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer","enrollment":25},{"nctId":"NCT06526104","phase":"PHASE2","title":"Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-12-02","conditions":"Hepatocellular Carcinoma, Cirrhosis, Liver","enrollment":32},{"nctId":"NCT07081633","phase":"PHASE2","title":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-05","conditions":"Hepatocellular Carcinoma","enrollment":114},{"nctId":"NCT05380713","phase":"PHASE2","title":"......SMARTEST Trial......","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-05-03","conditions":"Mesothelioma, Malignant","enrollment":30},{"nctId":"NCT06252753","phase":"","title":"Observational Study Protocol: LIVER-R","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-16","conditions":"Hepatobiliary Cancers","enrollment":4490},{"nctId":"NCT04960709","phase":"PHASE3","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-08-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":712},{"nctId":"NCT06880523","phase":"PHASE2","title":"STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-10-21","conditions":"Hepatocellular Carcinoma","enrollment":140},{"nctId":"NCT04430452","phase":"PHASE2","title":"Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Mary Feng, MD","startDate":"2022-02-04","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8","enrollment":21},{"nctId":"NCT04238637","phase":"PHASE2","title":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2019-11-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT06564623","phase":"PHASE1","title":"Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-05-27","conditions":"Biliary Tract Cancers","enrollment":25},{"nctId":"NCT03249142","phase":"PHASE1, PHASE2","title":"Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2017-10-18","conditions":"Ovarian Cancer","enrollment":69},{"nctId":"NCT02639026","phase":"PHASE1","title":"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2016-01-26","conditions":"Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC)","enrollment":53},{"nctId":"NCT03703297","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Small Cell Lung Cancer","enrollment":730},{"nctId":"NCT06994299","phase":"PHASE2","title":"A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT03911557","phase":"PHASE2","title":"Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2019-06-08","conditions":"Tumor, Solid","enrollment":14},{"nctId":"NCT07226063","phase":"PHASE2","title":"Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer","status":"NOT_YET_RECRUITING","sponsor":"Amit Mahipal","startDate":"2026-02","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":16},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT03581487","phase":"PHASE1, PHASE2","title":"Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-01","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":40},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT03043872","phase":"PHASE3","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-03-27","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":987},{"nctId":"NCT06058663","phase":"PHASE1","title":"Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-06","conditions":"Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":16},{"nctId":"NCT03237377","phase":"PHASE2","title":"Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-12-12","conditions":"Non-Small Cell Lung Cancer","enrollment":9},{"nctId":"NCT05932199","phase":"PHASE1, PHASE2","title":"Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2024-07-03","conditions":"Mesothelioma","enrollment":52},{"nctId":"NCT02938793","phase":"PHASE2","title":"Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors","status":"TERMINATED","sponsor":"Prisma Health-Upstate","startDate":"2016-12-01","conditions":"Cancer, Rare Disease","enrollment":92},{"nctId":"NCT03026062","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-18","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":100},{"nctId":"NCT03019003","phase":"PHASE1","title":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-03-20","conditions":"Head and Neck Cancer","enrollment":13},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT07168668","phase":"PHASE2","title":"Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-15","conditions":"HCC, Tace, Immunotherapy","enrollment":90},{"nctId":"NCT06999694","phase":"PHASE2","title":"Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-22","conditions":"HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab","enrollment":45},{"nctId":"NCT04605731","phase":"PHASE1","title":"Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-08-03","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT02962063","phase":"PHASE1, PHASE2","title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT05701488","phase":"PHASE1","title":"SIRT With Tremelimumab and Durvalumab for Resectable HCC","status":"RECRUITING","sponsor":"Jiping Wang, MD, PhD","startDate":"2023-04-21","conditions":"Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer","enrollment":20},{"nctId":"NCT03385655","phase":"PHASE2","title":"Prostate Cancer Biomarker Enrichment and Treatment Selection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-08-01","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT03638141","phase":"PHASE2","title":"CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT06109272","phase":"PHASE2, PHASE3","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-01-11","conditions":"Hepatocellular Carcinoma","enrollment":660},{"nctId":"NCT07122089","phase":"PHASE2","title":"Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"Center Eugene Marquis","startDate":"2026-01-02","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":80},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT03267589","phase":"PHASE2","title":"Trial in Patients With Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2018-05-14","conditions":"Ovarian Cancer","enrollment":25},{"nctId":"NCT03704480","phase":"PHASE2","title":"Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2018-11-09","conditions":"Advanced Biliary Tract Carcinoma","enrollment":106},{"nctId":"NCT05451043","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-05","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer","enrollment":62},{"nctId":"NCT07027436","phase":"PHASE3","title":"Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-07-07","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT02815995","phase":"PHASE2","title":"Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-16","conditions":"Advanced and/or Metastatic Sarcoma","enrollment":57},{"nctId":"NCT03847649","phase":"PHASE2","title":"A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-03-09","conditions":"Cancer","enrollment":60},{"nctId":"NCT04817826","phase":"PHASE2","title":"TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2021-04-01","conditions":"Gastric Cancer, Microsatellite Instability","enrollment":31},{"nctId":"NCT06999707","phase":"PHASE2","title":"Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-22","conditions":"HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab","enrollment":45},{"nctId":"NCT03277482","phase":"PHASE1","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-06-01","conditions":"Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer","enrollment":16},{"nctId":"NCT02788773","phase":"PHASE2","title":"Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-12-15","conditions":"Prostate Cancer","enrollment":52},{"nctId":"NCT06911255","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Yoon Jun Kim","startDate":"2025-04-18","conditions":"Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT03212469","phase":"PHASE1, PHASE2","title":"A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-06-20","conditions":"Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer","enrollment":54},{"nctId":"NCT04585490","phase":"PHASE3","title":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","status":"RECRUITING","sponsor":"Maximilian Diehn","startDate":"2021-08-25","conditions":"Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc","enrollment":48},{"nctId":"NCT05239169","phase":"PHASE2","title":"Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-05-23","conditions":"Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma","enrollment":40},{"nctId":"NCT03601455","phase":"PHASE2","title":"Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-26","conditions":"Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8","enrollment":13},{"nctId":"NCT06045975","phase":"PHASE2","title":"Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-28","conditions":"HCC - Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT02879318","phase":"PHASE2","title":"Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-11-07","conditions":"Pancreatic Adenocarcinoma","enrollment":180},{"nctId":"NCT02879162","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-12-14","conditions":"Advanced Rare Tumours","enrollment":140},{"nctId":"NCT03871036","phase":"PHASE1, PHASE2","title":"Improve Checkpoint-blockade Response in Advanced Urothelial Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2019-05-01","conditions":"Urothelial Carcinoma","enrollment":53},{"nctId":"NCT06710223","phase":"PHASE1","title":"Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-01-03","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05557838","phase":"PHASE3","title":"Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-02-22","conditions":"Hepatocellular Carcinoma","enrollment":210},{"nctId":"NCT06806579","phase":"","title":"Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2022-12-21","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":1000},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":585,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MEDI4736 + Tremelimumab","genericName":"MEDI4736 + Tremelimumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEDI4736 (durvalumab) blocks PD-L1 to restore anti-tumor immunity, while tremelimumab blocks CTLA-4 to enhance T-cell activation, together providing dual checkpoint inhibition. Used for Unresectable or metastatic non-small cell lung cancer, Hepatocellular carcinoma, Mesothelioma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}